A data analysis from a randomized phase III clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer may benefit from adding Celebrex (celecoxib) to post-surgery treatment.
Julie In received a $1.9 million grant from the National Institute of Environmental Health Sciences to study the impact of uranium on the cells that line the intestines.
